ANROAlto Neuroscience, Inc.
$24.00+304% 1Y
$24.00
$5.6252 weeks$36.63
Latest close: back above its 200-day averageOct 8, 2026what changed →
ANRO as reported
- Net income
- −$84M
Net income · +30% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$69M
Free cash flow · +22% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.42
EPS · +1.3% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$84M | +30% | Q2 2026 |
| EPS | −$2.42 | +1.3% | Q2 2026 |
| ROE | −42% | n/a | Q2 2026 |
| ROA | −34% | n/a | Q2 2026 |
| ROIC | 935% | n/a | Q2 2026 |
| Free cash flow | −$69M | +22% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Alto Neuroscience, Inc. (ANRO) · Net incomeNet incomeAlto Neuroscience, Inc. (ANRO)
Biotechnology
The closest names by size in the same industry